The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care

Maria Antonietta Cerone; Tara C Mills; Rowena Sharpe; David McBride; Moira MacDonald; Suzanne MacMahon; Hood Mugalaasi; Pauline Rehal; Alessandro Rettino; Helen Roberts; Mark Ross; Donald Edward White; John Peden; Janette Rawlinson; Steffan N Ho; Simon Hollingsworth; Sanjay Popat; Gary Middleton; Peter Johnson; Charles Swanton; SMP2 consortium

doi:10.1038/s41416-022-02107-8

The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care

Br J Cancer. 2023 Jan;128(2):161-164. doi: 10.1038/s41416-022-02107-8. Epub 2023 Jan 4.

Authors

Maria Antonietta Cerone^#¹, Tara C Mills^#², Rowena Sharpe³, David McBride⁴, Moira MacDonald⁵, Suzanne MacMahon⁶, Hood Mugalaasi⁶, Pauline Rehal⁷, Alessandro Rettino⁷, Helen Roberts⁵, Mark Ross⁴, Donald Edward White¹, John Peden⁸, Janette Rawlinson⁹, Steffan N Ho¹⁰, Simon Hollingsworth¹¹, Sanjay Popat¹², Gary Middleton¹³, Peter Johnson¹⁴, Charles Swanton¹⁵; SMP2 consortium

Collaborators

SMP2 consortium:
Somai Man, Rachel Butler, Rhian White, Sian Morgan, Sian Wood, Lisa Thompson, Hedley Carr, Sumi Subramaniam, Cian McGuire, Helen Pitman, Isabella Chen, Kirsty Tunna, Sahar Rehman, Catrin Middleton, Abdullah Alvi

Affiliations

¹ Cancer Research Horizons, CRUK, The Francis Crick Institute, London, UK.
² Cancer Research UK, London, UK.
³ Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK.
⁴ Illumina Cambridge, Great Abington, Cambridge, UK.
⁵ All Wales Medical Genomics Service, University Hospital of Wales, Cardiff, UK.
⁶ The Centre for Molecular Pathology, The Royal Marsden, Sutton, UK.
⁷ West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
⁸ Genpax AG, Cambridge, UK.
⁹ Independent patient representative, Sandwell, West Midlands, UK.
¹⁰ Pfizer, Global Product Development Oncology, San Diego, CA, USA.
¹¹ AstraZeneca, Late Development Oncology, Academy House, Cambridge, UK.
¹² The Royal Marsden Hospital NHS Foundation Trust, London, UK.
¹³ Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham, UK.
¹⁴ School of Cancer Sciences, University of Southampton, Southampton, UK.
¹⁵ The Francis Crick Institute, Midland Road, London, UK. Charles.Swanton@crick.ac.uk.

^# Contributed equally.

Abstract

Genomic screening is routinely used to guide the treatment of cancer patients in many countries. However, several multi-layered factors make this effort difficult to deliver within a clinically relevant timeframe. Here we share the learnings from the CRUK-funded Stratified Medicine Programme for advanced NSCLC patients, which could be useful to better plan future studies.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / therapy
Humans
Lung Neoplasms* / genetics
Lung Neoplasms* / therapy
United Kingdom

Abstract

Publication types

MeSH terms

Grants and funding